These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 8119236)

  • 1. Graves' ophthalmopathy: current concepts regarding pathogenesis and management.
    Burch HB; Wartofsky L
    Endocr Rev; 1993 Dec; 14(6):747-93. PubMed ID: 8119236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunosorbent assay.
    Ahmann A; Baker JR; Weetman AP; Wartofsky L; Nutman TB; Burman KD
    J Clin Endocrinol Metab; 1987 Mar; 64(3):454-60. PubMed ID: 2434519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.
    Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR
    J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of immune damage in Graves' ophthalmopathy.
    Hiromatsu Y; Wang PW; Wosu L; How J; Wall JR
    Horm Res; 1987; 26(1-4):198-207. PubMed ID: 3596469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathogenetic connection between Graves' disease and chronic lymphocytic thyroiditis. (The role and incidence of thyroid stimulating antibodies).
    Leövey A; Bakó G; Sztojka I; Bordán L; Szabó T; Kálmán K; Balázs C
    Acta Med Acad Sci Hung; 1982; 39(1-2):1-6. PubMed ID: 6129766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease.
    Ross PV; Koenig RJ; Arscott P; Ludgate M; Waier M; Nelson CC; Kaplan MM; Baker JR
    J Clin Endocrinol Metab; 1993 Aug; 77(2):433-8. PubMed ID: 8345048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy.
    Heufelder AE
    Thyroid; 1995 Aug; 5(4):331-40. PubMed ID: 7488878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism.
    Kubota S; Gunji K; Ackrell BA; Cochran B; Stolarski C; Wengrowicz S; Kennerdell JS; Hiromatsu Y; Wall J
    J Clin Endocrinol Metab; 1998 Feb; 83(2):443-7. PubMed ID: 9467555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' ophthalmopathy--a clinical review.
    Carter JN
    Aust N Z J Ophthalmol; 1990 Aug; 18(3):239-42. PubMed ID: 2261168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
    de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graves' ophthalmopathy. A clinical and immunologic review.
    Sergott RC; Glaser JS
    Surv Ophthalmol; 1981; 26(1):1-21. PubMed ID: 6895125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves' ophthalmopathy and tobacco smoking.
    Tallstedt L; Lundell G; Taube A
    Acta Endocrinol (Copenh); 1993 Aug; 129(2):147-50. PubMed ID: 8103953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy.
    Salvi M; Bingoye F; Chung F; Wall JR
    J Clin Endocrinol Metab; 1988 May; 66(5):939-45. PubMed ID: 3360902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detectable serum IgE levels in Graves' ophthalmopathy.
    Molnár I; Horváth S; Balázs C
    Eur J Med Res; 1996 Sep; 1(11):543-6. PubMed ID: 9438158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dysthyroid optic neuropathy. Apropos of 2 cases].
    Domenjôd M; Merle H; Gerard M; Ayeboua L; Poman G
    J Fr Ophtalmol; 1996; 19(8-9):543-50. PubMed ID: 8944137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Graves' ophthalmopathy: reality and perspectives.
    Bartalena L; Pinchera A; Marcocci C
    Endocr Rev; 2000 Apr; 21(2):168-99. PubMed ID: 10782363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
    Molnár I; Balázs C
    Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.